Introduction
Recommendations for COPD treatment are primarily based on the burden of symptoms, categorized using the modified Medical Research Council and COPD assessment test questionnaires, and on risks, assessed based on severity of airflow limitation and history of exacerbations. 1 Studies have shown that coadministration of long-acting muscarinic antagonists (LAMAs) and long-acting β 2 -agonists (LABAs) is more effective than treatment with either drug class alone in stable COPD as the combination offers improvement in airflow obstruction, dynamic hyperinflation, reduction in rescue medication, and a safety profile that is similar to the components. . Studies have shown that UMEC/VI is well tolerated and offers greater improvements in lung function, health status, and dyspnea scores compared with placebo and better lung function compared with its monotherapy components and TIO. [5] [6] [7] [8] [9] UMEC/VI administration in a single inhaler (Anoro ® Ellipta ® ) has been approved by the US Food and Drug Administration and the European Medicines Agency as a OD maintenance treatment for airflow obstruction in patients with COPD. 10 The nominal dose of UMEC/VI is 62.5/25 μg OD per the US label, whereas the actual dose delivered is 55/22 μg mentioned in the European Union label. Similarly, several studies have evaluated the safety and efficacy of other open-combination dual bronchodilators with a variety of dosing regimens, such as FOR + TIO (12 μg metered dose/10 μg delivered dose twice daily (bid) +18 μg OD), SAL + TIO (50 μg bid +18 μg OD), IND + TIO (150 μg +18 μg OD), and QVA149 (nominal dose, 110/50 μg OD; delivered dose, 85/43 μg OD) in patients with moderateto-very severe COPD. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] With the recent introduction of a new class of fixed-dose combination bronchodilators (UMEC/VI and QVA149) 22, 23 and several others under development, assessing their efficacy relative to each other and with open dual combinations is desirable. Therefore, this study aimed to perform a systematic literature review (SLR) and to synthesize, by means of a Bayesian network meta-analysis (NMA), the published evidence on the efficacy of the fixed combination of UMEC/VI (55/22 μg OD) with that of all available dual-bronchodilator combinations in single or separate inhalers. The relative efficacy of the treatments was assessed at 12 weeks and 24 weeks by means of difference in change from baseline (CFB) on lung function (trough forced expiratory volume in 1 second [FEV 1 ]), health status (St George's Respiratory Questionnaire [SGRQ] total score), difference in transitional dyspnea index (TDI) focal score, and difference in rescue medication use.
Methods

Data sources
The study protocol was approved by GSK internal protocol review committee. Since the study was based on data extracted from published literature, it was exempt from human subjects review.
An SLR was conducted to identify randomized controlled trials (RCTs) comparing UMEC/VI with alternative LABA/ LAMA open and fixed combinations, using appropriate databases and registries from their inception up to . RCTs in English language were included. A broad search strategy was employed to cover the entire range of available LABA, LAMA, or LABA/LAMA comparators. Details of the databases, selection criteria, and the search strategies are presented in Tables S1 and S2, respectively.
Inclusion criteria and study selection process
Identified abstracts were independently assessed by two reviewers as per predefined selection criteria: patient population -adult COPD patients (age $40 years of any race and sex); interventions -UMEC/VI; comparators -LABA/ LAMA, placebo, TIO 18 μg (henceforth, TIO = TIO 18 μg); outcomes -FEV 1 , SGRQ total scores, TDI focal scores, and rescue medication use; study design -RCTs of $10-week duration.
Studies were included in the SLR if they compared interventions of interest in the analysis with each other or with placebo. During the SLR protocol development, it was known that three of UMEC/VI RCTs (clinical study reports provided by GlaxoSmithKline) had TIO as comparator. Due to this, we decided to include TIO as one of the comparators in the selection criteria. Because both TIO and placebo were selected as potential common comparators, studies comparing TIO with placebo were also of interest to strengthen the network.
Data abstraction and quality assessment
For studies that met the selection criteria, the following information was extracted: study design, patient characteristics, types of intervention and comparators, outcomes of interest, and patient withdrawals with reasons for withdrawal.
For each trial, the mean difference in CFB between the arms of interest (or least square mean) and the 95% confidence interval (95% CI), standard error (SE), or standard deviation (SD) were abstracted, where available. If not reported, the difference in CFB was calculated based on the CFB (or least square mean) per treatment arm. If not reported, the SE was imputed using the uncertainty of other trials in the network. A checklist for RCTs based on the guidance by the Institute for Quality and Efficiency in Health Care was used for risk of bias assessment. 24 An effect modifier is a study or patient characteristic that influences the treatment effect. Because of the randomization process, potential effect modifiers are expectedly balanced between treatment arms within an RCT. However, an NMA involves different trials comparing different interventions. Therefore, the distribution of effect modifiers not only varies 
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UMEC/VI versus other combination bronchodilators in COPD across studies for a particular comparison (heterogeneity) but also between comparisons (inconsistency). Although slight variations in patient characteristics across studies are always expected, an NMA is only valid when no imbalances exist in effect modifiers across comparisons. To reduce the risk of biased outcomes in the NMA, data from only studies that are similar with respect to patient populations and study designs should be compared. 25, 26 The similarity of studies was assessed by evaluating the distribution of patient characteristics and study design across the direct comparisons in the network. If major imbalances in patient or study characteristics were detected that could influence the treatment effect, scenario analysis was used to explore the inhomogeneity. Meta-regression techniques could not be used to adjust for variations due to the limited number of studies available in the network.
Data synthesis
The identified trial evidence was used to perform an NMA within a Bayesian framework to simultaneously synthesize the results of the included studies and to obtain relative treatment effects. A linear model with normal likelihood distribution was used with flat (noninformative) prior distributions assumed for all outcomes. Prior distributions of the relative treatment effects were normal, with zero mean and a variance of 10,000. A uniform distribution ranging from zero to five was used as the prior of the interstudy SD.
For each outcome, fixed-and random-effects models were evaluated. The goodness of fit of each model to the data was assessed using the Deviance Information Criterion. The posterior densities for the outcomes of interest were estimated using the Markov Chain Monte Carlo simulations for each model. The results were based on 80,000 iterations on three chains, with a burn-in of 20,000 iterations. Convergence assessment was based on visual inspection of trace plots. Accuracy of the posterior estimates was assessed using the Monte Carlo error for each parameter (Monte Carlo error ,1% of the posterior SD). The models used in this study were based on those defined by Dias et al 27 and were implemented using WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).
The posterior distributions were summarized with the corresponding median values to reflect the most likely value of the estimate, and the 2.5 and 97.5 percentile to capture the 95% credible interval (95% CrI), which represents the range of true underlying effects with 95% probability. Pairwise comparisons for all treatments included in the network were calculated, including the relative effectiveness and the probability of each treatment being better than each of the rest. If studies reported mean values without any measure of uncertainty (SE, SD, 95% CI), scenario analyses were performed excluding this study because of the lack of data; however, such studies were included with the reported mean value and an imputation for the SE.
The feasibility of an NMA to compare LABA/LAMA treatments with each other or with placebo was assessed. Considering the lack of placebo-controlled LABA/LAMA studies, TIO was included in the network to allow indirect comparisons with more treatments of interest. Extending the network by including TIO does have potential advantages such as strengthening inference and producing a more robust analysis. Two sets of analyses were performed, one including only LABA/LAMA treatments and placebo in the network (data not shown) and the other including LABA/LAMA treatments, TIO, and placebo in the network. The second analysis (including TIO) allowed for indirect comparisons with more relevant open and closed dual comparators because many studies lacked a placebo arm.
Results
Search and selection results
In total, 3,006 abstracts were identified, of which, 309 (10.3%) abstracts were of interest based on predefined selection criteria, and full-text articles were obtained (Figure 1 ). Of the 4,720 identified registries, 159 were included. The registry screening results were merged with the abstracts and were screened against full-text selection criteria. The final NMA evidence base comprised 77 articles relating to 26 trials. These trials represented RCTs comparing LABA/LAMA combinations approved as of and TIO with each other or with placebo. The efficacy parameters shared between trials included lung function, defined as a difference in CFB in trough FEV 1 and patient-reported outcomes, such as mean CFB in SGRQ total scores, difference in mean TDI focal scores, and change in rescue medication use estimated as mean number of puffs per day. Changes in efficacy parameters were compared at the 3-month (12-week) and 6-month time points (range, 24-26 weeks), to correspond to the duration of the UMEC/VI comparator trials (Table 1 ).
An overview of the study design, inclusion criteria, and background treatments of these trials is presented in Table 1 . Study participants included individuals aged $40 years with an established diagnosis of COPD and a smoking history of $10 pack-years. Patients with moderate-to-very severe (GOLD stages II-IV) COPD, with an FEV 1 of #70% of predicted normal value, and no inclusion criterion related to the number of exacerbations in the previous year were considered 21 ; potential exceptions were the SPARK study, which included no patients with moderate COPD, but only patients with a history of .1 moderate or severe exacerbation during the past year, 16 and the UMEC/VI studies, all of which included patients who had breathlessness (modified Medical Research Council scale $2). 6, 9, 28 Regarding the background treatments, most of the studies allowed the use of inhaled corticosteroids (ICSs), while the use of LAMAs, LABAs, or LABA/ICS was not allowed. Table 2 presents an overview of the primary patient characteristics (and potential treatment effect modifiers in COPD), including age, sex, smoking status, ICS use, COPD duration, number of pack-years, predicted FEV 1 , and proportion of patients with severe or very severe disease. The patients were primarily male (49%-99%), with a mean age above 60 years (60-68 years) and heavy smokers (36-69.2 pack-years). Some variation in ICS use was detected (25%-76%), with Aaron et al 20 and Tashkin et al 18 reporting that ,30% of patients used ICS at baseline in at least one of the treatment arms.
Overall, patient characteristics were comparable between UMEC/VI and other dual-bronchodilator trials. No major imbalances in the study and patient characteristics were observed between direct comparisons in the network that could act as effect modifiers of the relative treatment effects; therefore, an NMA was deemed to be feasible. 26 The results of the risk of bias assessment at study level for all studies included in the NMA are summarized in Table S3 . 
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UMEC/VI versus other combination bronchodilators in COPD Bayesian NMA Figure 2 presents the overall network of studies in the analysis. These studies were identified in the SLR comparing QVA149, FOR + TIO, SAL + TIO, IND + TIO, or UMEC/VI with TIO OD or placebo as common comparators. The common endpoints in the identified studies were trough FEV 1 , SGRQ total scores, TDI focal scores, and rescue medication use at 24 weeks and within the time margins around these time points.
Trough FEV 1
In total, 14 studies were included for the FEV 1 endpoint (Figure 2 and Table 3 ). Figure 3A and Table 4 ).
sgrQ total scores
Fourteen studies were included in the analysis of SGRQ total scores ( Figure 2 and Table 3 ). All the combination therapies, including UMEC/VI, QVA149, TIO + SAL, and TIO + FOR, demonstrated significantly higher efficacy in CFB in SGRQ total scores compared with placebo and TIO at 24 weeks. UMEC/VI was not significantly different from QVA149 (ED, 0.18; 95% CrI: −1.28, 1.63), TIO + SAL (ED, −0.11; 95% CrI: −1.84, 1.61), and TIO + FOR (ED, −0.68; 95% CrI: −1.77, 0.40) ( Figure 3B and Table 4 ). As a scenario analysis, SE was imputed for the study by Donohue et al (TIO vs placebo), 29 and this study was included in the network, having marginal impact on the results.
TDI focal scores
In total, ten studies were included in the TDI analysis ( Figure 2 and Table 3 ). Combination therapies of UMEC/VI and QVA149 were more efficacious than placebo, and QVA149 was more efficacious than TIO monotherapy in TDI focal score at 24 weeks. UMEC/VI was not significantly different from QVA149 (ED, −0.30; 95% CrI: −0.73, 0.13) and TIO + SAL (ED, 0.58; 95% CrI: −0.33, 1.50) ( Figure 3C and Table 4 ). The addition of imputed evidence from the Donohue et al study 29 had marginal impact on the results. Abbreviations: CI, confidence interval; FEV 1 , forced expiratory volume in 1 second; FOR, formoterol; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; NMA, network meta-analysis; PBO, placebo; QVA149, indacaterol/glycopyrronium; SAL, salmeterol; SD, standard deviation; SE, standard error; SGRQ, St George's Respiratory Questionnaire; TDI, transitional dyspnoea index; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.
rescue medication use
In total, seven studies were included in the rescue medication use network ( Figure 2 and Table 3 ). For rescue medication use at 24 weeks, the combination therapies of UMEC/VI and QVA149 were more efficacious than placebo and TIO. No significant difference was observed between UMEC/VI and QVA149 (ED, 0.02; 95% CrI: −0.27, 0.32) ( Figure 3D and 
Discussion
This study evaluated the comparative efficacy of UMEC/VI 55/22 μg with all the available open and closed dual-combination bronchodilators in patients with moderate-to-very severe COPD who were eligible to receive maintenance bronchodilator therapy. Four endpoints, including mean CFB in trough FEV 1 , CFB in SGRQ total scores, TDI focal scores, and CFB in rescue medication use, were selected and analyzed because they were consistently reported across all the studies and deemed as important endpoints in clinical practice. The Bayesian NMA showed that for each endpoint, UMEC/VI was similar to all the other dual fixed or open LABA/LAMA combination bronchodilators (IND + TIO, TIO + SAL, TIO + FOR, and QVA149) available at the time of this analysis. Indirect treatment comparison within a frequentist framework by using Bucher's method also showed consistent results for all the aforementioned efficacy parameters (data not shown). 30 This suggests that combination therapies of LABA/LAMA are broadly comparable across the most common endpoints evaluated in RCT settings. These aforementioned observations are consistent with two other recent NMAs, which suggested that bronchodilator monotherapies are broadly similar across a range of clinical endpoints. 31 One NMA, however, showed that newer OD LABAs were likely to be more effective compared with bid LABAs at improving FEV 1 and SGRQ scores. 32 The NMA focused on four most commonly 
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UMEC/VI versus other combination bronchodilators in COPD Table 3 Individual study results at 12 weeks and 24 weeks for trough FEV reported endpoints in RCTs of bronchodilators. Endpoints such as adverse events, exercise tolerance, and exacerbations were excluded. Our feasibility assessment suggested that the definitions of adverse events, exacerbations, and exercise tolerance tests used in manufacturer-conducted trials differed significantly across various LABA and/or LAMA treatments, preventing robust comparison. The patients assessed in most trials reported a limited history of exacerbations and in those trials enriched for patients with exacerbations; no placebo comparisons were included. Moreover, exacerbation was not a key endpoint in most selected studies, including the UMEC/ VI studies. Patients with exacerbations were withdrawn from UMEC/VI studies at the first event, 6, 9, 28 thereby limiting the available evidence to the risk of a first event but providing no data on exacerbation rates. Other trials designed to examine exacerbations included the SPARK study, 16 in which the LABA/LAMA combination (QVA149) was compared with two LAMAs and was reported to provide superior reductions in the rate of moderate or severe exacerbations versus GLY but not versus TIO. This benefit of QVA149 was also entirely confined to patients using concurrent corticosteroids. 16 Similarly, Aaron et al 20 reported no exacerbation benefit with TIO + SAL versus TIO in patients not using corticosteroids. In the UMEC/VI studies, approximately 50% of patients used corticosteroids and a superior exacerbation benefit was observed on the time to the first exacerbation with UMEC/VI versus placebo 6 and versus TIO but only in the largest of three similar 6-month trials. 28 Consequently, uncertainty still exists on this endpoint, which is out of scope for this NMA.
These meta-analyses also demonstrated that monobronchodilators when compared with placebo generally failed to improve total SGRQ scores by $4 units and TDI focal scores by $1 unit at 6 months, which are the minimal clinically important differences for each of these commonly used patientreported outcomes, even when the trough FEV 1 improved by at least 100 mL compared with placebo. 32 In the current analysis, we observed that UMEC/VI consistently demonstrated clinically important benefits versus placebo and statistically significant benefits versus TIO at 6 months, which were broadly comparable to any alternative dual-bronchodilator combinations. These findings highlight that LAMA or LABA monotherapy alone may not always provide all patients with sustained benefits enabling freedom from recurrence of COPD symptoms. 33 Dual bronchodilators, which are sparingly used in current clinical practice, may provide optimal symptom control in addition to maximum bronchodilation to appropriate COPD patients. 34 Overall, both QVA149 and UMEC/VI demonstrated beneficial effects compared with monotherapy at 24 weeks, .99%
.99%
Notes: Differences in intervention versus the comparator for CFB in trough FEV 1 (mL), SGRQ total scores, TDI focal scores, and rescue medication use at 12 weeks and 24 weeks, 95% CrI, and probability (P) that the intervention is better than the comparator. Blank spaces in the 
Limitations
A potential limitation of this analysis is the low number of studies for some of the treatments (eg, TIO18 + SAL50) and the absence of direct evidence with other active treatments of interest. The fact that for these treatments only indirect comparison (via TIO or placebo) was available is reflected in the uncertainty of the relative efficacy results (ie, wide CIs). An additional limitation is that studies reporting data for aclidinium/FOR were not identified.
A further limitation of the analysis, as with all metaanalyses, is the potential influence of confounders. A metaregression to adjust for possible confounders was not feasible because of the limited number of studies included in each analysis. Although two studies 18, 20 reported lower ICS use at baseline, it was not possible to design scenario analyses excluding these studies. In both cases, it would result in the loss of a comparator in the network and would not affect the other relative efficacy estimates due to the shape of the network. Because recent NMAs 31, 32, 35 evaluating longacting bronchodilators in COPD did not suggest the relative efficacy estimates to be greatly affected by this and other potential effect modifiers, the impact of this imbalance was not believed to be a likely source of bias. Although the studies were similar enough to be included in an NMA, residual confounding may exist in these aggregated data.
Conclusion
Based on the results of this 6-month NMA of the available RCTs reporting on efficacy outcomes in terms of trough FEV 1 , SGRQ total scores, TDI focal scores, and rescue medication use, UMEC/VI is comparable to QVA149 and is expected to be at least comparable to the remaining dualbronchodilator combinations.
Statement of originality/clinical relevance
With the recent introduction of a new class of fixed-dose combination bronchodilators (UMEC/VI and QVA149) and several others under development, assessing their efficacy
